Multiple studies show nu.q® nets test could predict sepsis patients at risk of deteriorating

Henderson, nev. , oct. 31, 2024 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company, has published a report , from its 'nets in sepsis management' symposium at esicm lives 2024 last month, which concluded that nu.q® nets could be used to predict patients at greater risk of deteriorating from sepsis.
VNRX Ratings Summary
VNRX Quant Ranking